Skip to main content
Prof. Hartmann interviewed by Dr. Barbara Kreppel for 'Angewandte Nuklearmedizin'

Publication

Immunology and Nuclear Medicine

Prof. Gunther Hartmann was interviewed for the magazine “Angewandte Nuklearmedizin” and answered questions about immunology and nuclear medicine.

Dr. Barbara Kreppel from the magazine “Angewandte Nuklearmedizin” interviewed Prof. Gunther Hartmann, director of the Institute of Clinical Chemistry and Clinical Pharmacology and founding speaker of the ImmunoSensation2 Cluster of Excellence, on his expertise on immunology and nuclear medicine. 

During the interview, Prof. Gunther Hartmann shed light on emerging trends in the research fields of immune-oncology and autoimmunity, emphasizing the potential of nuclear medicine for the development of diagnostic tools and novel therapies. He gave an interesting perspective on how nuclear medicine advancements could help with cancer therapy and highlighted the importance of nuclear medicine for immune imaging.

The full interview can be found in the latest issue of “Angewandte Nuklearmedizin”.

Interview:

Angewandte Nuklearmedizin 2024; 47: 78–79
DOI 10.1055/a-2183-2133
ISSN 2749-7445
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG, Rüdigerstraße 14,
70469 Stuttgart, Germany

Press contact:

Dr. Barbara Kreppel
Universitätsklinikum Bonn
Klinik und Poliklinik für Nuklearmedizin
Venusberg-Campus 1
53127 Bonn
E-Mail: barbara.kreppel@ukbonn.de

Related news

AG Kürthen Multiple Sclerosis Bonn

Publication

Potential target for MS therapy discovered

—Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system caused by the immune system. B cells, which are a type of white blood cell, play a role in the development of MS and are thus a target for therapies. Researchers at the University Hospital Bonn (UKB), the University of Bonn and the FAU Erlangen-Nuremberg identified the membrane protein MLC1 as a potential target antigen in MS. The results of the work have now been published in the renowned journal “Neurology Neuroimmunology & Neuroinflammation”.
View entry
NLRP3 Alzheimers McManus

Publication

Reducing Neuroinflammation Could Help Fight Alzheimer’s

—Alzheimer’s disease is the most common cause of dementia. A promising approach for its treatment is the prevention of inflammatory processes in the brain. An international team of scientists around Dr. Róisín McManus, Prof. Eicke Latz and Prof. Michael Heneka now provide new evidence supporting this approach and potentially contributing to the development of more effective therapies. The results have now been published in the journal “Immunity”.
View entry
Bipolar disorder News Noethen

Publication

Large study on the genetics of bipolar disorder

—Genetic factors play a major role in the development of bipolar disorder. In an effort to better understand the underlying biology, researchers are constantly studying the genetic makeup of people with bipolar disorder. The Psychiatric Genomics Consortium's Genome-Wide Association Study (GWAS) is the largest of its kind. The study analyzes data from ver 150,000 people of European, East Asian, African-American and Latin American descent. The latest results have now been published in the renowned scientific journal “Nature”.
View entry

Back to the news overview